September 18, 2023

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit

Avalyn CEO, Lyn Baranowski will lead a workshop during the IPF Summit on clinical trial strategies for pulmonary fibrosis therapies

September 12, 2023

Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis

Data were presented at ERS 2023 showing that treatment with AP01 preserved forced vital capacity in participants in the ongoing AP01-005 open label extension study.

September 11, 2023

Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer

Avalyn appointed Melissa Rhodes, Ph.D., a business operations leader with extensive expertise in respiratory medicine, to the role of chief operating officer.

September 7, 2023

Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress

Interstitial lung disease experts will present FVC findings from Phase 1b ATLAS study of AP-01 at European Respiratory Society’s Congress

August 7, 2023

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Avalyn announced that it has appointed pulmonary and critical care physician, Howard M. Lazarus, M.D., FCCP, to the newly created position of chief medical officer.

July 27, 2023

Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference

Avalyn CEO Lyn Baranowski will participate in a fireside chat during the 2023 Canaccord Genuity Growth Conference August 10 in Boston

June 15, 2023

Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June

Avalyn leadership is presenting the corporate and produce development strategy at June conferences hosted by H.C. Wainwright and Hanson & Wade

May 23, 2023

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01

Long-term efficacy and tolerability data presented by Avalyn at ATS 2023 indicate a durable and consistent response to AP01 therapy

May 11, 2023

Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)

Avalyn showcasing therapeutic approach to life-threatening respiratory diseases at upcoming ATS annual meeting being held May 19-24, 2023.

May 10, 2023

Avalyn Pharma Presenting at BioEquity Europe

Lyn Baranowski is planning to present a corporate update during BioEquity Europe, which is being held May 14-16, 2023 in Dublin, Ireland

April 11, 2023

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis

Top-line results are reported from the open-label extension trial of AP01 in participants with idiopathic and progressive pulmonary fibrosis

March 30, 2023

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

Top-line data from Phase 1 trial showed that AP02 (inhaled nintedanib) was well tolerated in healthy volunteers and adults with idiopathic pulmonary fibrosis (IPF)

March 23, 2023

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

Results from the Phase 1b ATLAS study of AP01 (inhaled pirfenidone) in adults with IPF were published online in the journal, Thorax.

November 28, 2022

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference

Avalyn Pharma’s chief executive and chief financial officers will participate in a fireside chat during the annual Evercore ISI HealthCONx Conference

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer

Avalyn welcomes CEO, Lyn Baranowski, who brings a career of respiratory disease experience from Altavant Sciences, Pearl Therapeutics and Novartis

October 27, 2021

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer

Avalyn Pharma welcomes CFO, Marc Schneebaum, who brings financial strategy and business development experience from an array of biotechnology companies

May 24, 2021

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial

Avalyn presented results from a Phase 1/2 study, in which lung function was maintained among the high-dose AP01 (inhaled pirfenidone) group

October 16, 2020

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial

Avalyn Pharma announced completion of last patient in the initial 24 week evaluation of AP01 in a Phase 1/2 study

April 27, 2020

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio

Avalyn Pharma announced the completion of a $35.5 million Series B round led by Norwest Venture Partner

May 15, 2017

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team

Genoa Pharmaceuticals completed a $62 million Series A financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners

August 5, 2014

Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)

The U.S. Food and Drug Administration has granted orphan-drug designation to Genoa for the use of pirfenidone in GP-101, the company's lead candidate for the treatment of IPF

May 13, 2014

Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference

Genoa Pharmaceuticals announced that it will highlight research conducted with inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis during the 2014 American Thoracic Society International Conference

April 21, 2014

Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability

Genoa Pharmaceuticals reported results from an in vivo study of inhaled GP-101 in the treatment of pulmonary fibrosis